Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GnRH Agonist vs Antagonist Protocols in IVF with PGS/PGD
NCT01636505Phase 3
Key facts
- Status
- Unknown
- Start
- Sep 2012
- Primary completion
- Feb 2013
- Countries
- 1
- Sponsor
- European Hospital
- Modality
- Peptides, Small Molecules
- Conditions
- infertility
01
Overview
Phase 3, randomised trial of cetrorelix, ganirelix and buserelin in infertility (2 arms), sponsored by European Hospital. Primary endpoint: Rate of genetic and chromosomal abnormalities in embryos at 1 year. Status: unknown.
02
Design
2 arms- Study design
- Randomized
short protocol
GnRH antagonist (cetrotide/orgalutran) ovarian stimulation
long protocol
GnRH agonist (suprefact) ovarian stimulation
03
Who it enrols
Patients with advanced maternal age, repeated IVF failure, recurrent pregnancy loss, or carriers of genetic diseases. Excludes uterine abnormalities, endometriosis, and endocrinal diseases.
04
Endpoints
Primary
Rate of genetic and chromosomal abnormalities in embryos
Secondary
Pregnancy rate
Implantation rate
Healthy baby birth rate
Beyond the preview
Go deeper on NCT01636505.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01636505.